在喘中推进精确医学:治疗结果的演变
Giorgio Walter Canonica1, Gilda Varricchi2, Giovanni Paoletti1
1Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, Italy; Asthma & Allergy Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, Milan, Italy.
The Journal of allergy and clinical immunology
|August 2, 2023
概括
生物药物和过敏原免疫疗法 (AIT) 提供个性化喘治疗,可能改变呼吸道改造和疾病进展. 将这些先进疗法结合起来,有望改善过敏性喘的结果.
科学领域:
- 肺病学和过敏症的研究
- 药理学 药理学是指药理学的学科.
- 免疫治疗是一种免疫疗法.
背景情况:
- 喘治疗已经从一般方法发展到个性化医疗.
- 严重的喘涉及复杂的机制,如气道改造.
- 目前的治疗方法旨在控制症状,但疾病修改是关键目标.
研究的目的:
- 审查喘治疗方面的进展,重点关注生物药物和过敏原免疫疗法 (AIT).
- 探索生物药物和AIT在修改气道改造和疾病过程中的潜力.
- 讨论以患者为中心的治疗结果和喘缓解的作用.
主要方法:
- 关于历史和最近喘治疗策略的文献综述.
- 对生物药物对严重喘呼吸道改造的影响的分析.
- 对过敏性喘的综合生物和AIT方法的评估.
主要成果:
- 生物药物显示出针对呼吸道重塑的潜力,这是慢性喘的标志.
- 疾病修饰性抗喘药物旨在改变喘的自然过程.
- 将生物药物与AIT结合,在过敏性喘研究中显示出改善的临床结果.
- 喘缓解正在成为一个重要的以患者为中心的结果措施.
结论:
- 生物制剂和AIT代表了向个性化呼吸道过敏治疗的转变.
- 生物药物和AIT的结合为过敏性喘提供了一个新的治疗策略.
- 需要进一步的研究,以优化在严重喘中使用AIT,特别是与生物药物结合使用.
相关概念视频
Asthma: Pathogenesis and Management
446
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
446
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
346
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
346
Asthma-IV: Nursing Management
3.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.1K
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K


